Research information is easier to assess when each claim is connected to an identifiable source. A company description, an analytical certificate and a clinical publication serve different purposes. This guide explains how to read those materials without treating them as interchangeable evidence.
Understanding analytical documentation
For pharmaceutical ingredients, FDA’s ICH Q7 guidance describes information to include in a certificate of analysis. This includes the material and batch identifiers, the tests performed, acceptance limits and reported results.
The guidance concerns pharmaceutical manufacturing. Whether any particular organisation follows it requires separate evidence. A reference to a standard does not establish a company’s certification or compliance.
Questions to ask about a document
- Can the document be connected to a specific material and batch?
- Does it identify the tests, results and relevant limits?
- Is the issuer identified, and is the document dated?
- Does the accompanying claim stay within what the document actually reports?
A reported result should be interpreted in the context of its test and sample. Missing information should remain an unanswered question rather than being replaced with an assumption about quality or suitability.
Separating documentation from clinical evidence
The NIH guide to clinical trials explains how research protocols define the study population, procedures, duration and outcomes. Those details help readers assess the scope of a clinical finding.
An analytical certificate cannot replace that clinical evidence. Equally, a published study does not authenticate a separately supplied material. Claims about a company’s testing, policies or practices should link to the specific supporting documents, while scientific claims should link to the relevant research.